Walleye Capital LLC Has $1.55 Million Stock Holdings in Annexon, Inc. $ANNX

Key Points

• Walleye Capital LLC has increased its stake in Annexon, Inc. by 22.3% by acquiring an additional 146,581 shares, bringing its total ownership to 802,913 shares valued at approximately $1.55 million.
• Several hedge funds have also adjusted their positions in Annexon, with Forefront Analytics LLC significantly increasing its holdings by 74.0%.
• Despite recent buy ratings from multiple analysts, Annexon shares have experienced a decline of 2.8% and are trading at $2.06, significantly lower than their 12-month high of $7.85.

Walleye Capital LLC increased its position in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) by 22.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 802,913 shares of the company's stock after acquiring an additional 146,581 shares during the period. Walleye Capital LLC owned about 0.73% of Annexon worth $1,550,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of ANNX. Forefront Analytics LLC raised its holdings in shares of Annexon by 74.0% during the first quarter. Forefront Analytics LLC now owns 28,591 shares of the company's stock worth $55,000 after acquiring an additional 12,158 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Annexon during the fourth quarter worth $59,000. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Annexon by 164.1% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 34,026 shares of the company's stock worth $66,000 after acquiring an additional 21,143 shares in the last quarter. Hsbc Holdings PLC raised its holdings in shares of Annexon by 19.9% during the first quarter. Hsbc Holdings PLC now owns 36,935 shares of the company's stock worth $73,000 after acquiring an additional 6,136 shares in the last quarter. Finally, EntryPoint Capital LLC purchased a new stake in shares of Annexon during the first quarter worth $103,000.

Analyst Ratings Changes

Several analysts recently issued reports on ANNX shares. HC Wainwright reiterated a "buy" rating and set a $14.00 price objective on shares of Annexon in a report on Friday, August 15th. Zacks Research raised shares of Annexon from a "strong sell" rating to a "hold" rating in a research report on Monday, August 18th. Finally, Needham & Company LLC lowered their target price on shares of Annexon from $16.00 to $11.00 and set a "buy" rating on the stock in a research report on Tuesday, May 13th. Three analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $12.50.

Annexon Trading Up 0.7%

Annexon stock traded up $0.02 during mid-day trading on Wednesday, hitting $2.09. 525,745 shares of the company's stock were exchanged, compared to its average volume of 1,537,001. The stock has a market cap of $229.12 million, a P/E ratio of -1.61 and a beta of 1.15. Annexon, Inc. has a 1-year low of $1.28 and a 1-year high of $7.85. The stock has a 50 day moving average of $2.43 and a two-hundred day moving average of $2.26.

Annexon (NASDAQ:ANNX - Get Free Report) last issued its quarterly earnings results on Thursday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.36) by $0.02. As a group, research analysts predict that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.